Ixaltis
Ixaltis is a pharmaceutical biotechnology company focused on developing treatments for genitourinary tract disorders. The company manages a pipeline of clinical compounds, including Litoxetine (IXA-001), which is currently in Phase II clinical trials for female subjects. Their research and development efforts are based on molecules licensed exclusively from Sanofi to address urogenital health conditions.
Visit websiteToulouse, France
Biotechnology
Pharmaceuticals
Healthcare
Funding summary
- Total raised
- €10.8M
- Funding rounds
- 2
Investors in Ixaltis
Investors on record for Ixaltis. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Ixaltis?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors